Cargando…

Risk Factors for Peritoneal Recurrence in Stage II to III Colon Cancer

BACKGROUND: Most previous reports to analyze risk factors for peritoneal recurrence in patients with colon cancer have been observational studies of a population-based cohort. OBJECTIVE: This study aimed to determine the risk factors for peritoneal recurrence in patients with stage II to III colon c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mayanagi, Shuhei, Kashiwabara, Kosuke, Honda, Michitaka, Oba, Koji, Aoyama, Toru, Kanda, Mitsuro, Maeda, Hiromichi, Hamada, Chikuma, Sadahiro, Sotaro, Sakamoto, Junichi, Saji, Shigetoyo, Yoshikawa, Takaki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott 2018
Materias:	Original Contributions
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6012056/ https://www.ncbi.nlm.nih.gov/pubmed/29561282 http://dx.doi.org/10.1097/DCR.0000000000001002

Ejemplares similares

Clinical impact of tumor location on the colon cancer survival and recurrence: analyses of pooled data from three large phase III randomized clinical trials
por: Aoyama, Toru, et al.
Publicado: (2017)

Hazard rate of tumor recurrence over time in patients with colon cancer: implications for postoperative surveillance from three Japanese Foundation for Multidisciplinary Treatment of Cancer (JFMC) clinical trials
por: Maeda, Hiromichi, et al.
Publicado: (2017)

Impact of postoperative complications on the colorectal cancer survival and recurrence: analyses of pooled individual patients’ data from three large phase III randomized trials
por: Aoyama, Toru, et al.
Publicado: (2017)

Development and validation of a prognostic nomogram for colorectal cancer after radical resection based on individual patient data from three large-scale phase III trials
por: Honda, Michitaka, et al.
Publicado: (2017)

The clinical impacts of postoperative complications after colon cancer surgery for the clinical course of adjuvant treatment and survival
por: Aoyama, Toru, et al.
Publicado: (2023)

Randomized phase III trial comparing surgery alone to UFT + PSK for stage II rectal cancer (JFMC38 trial)
por: Okuno, Kiyotaka, et al.
Publicado: (2017)

Phase III randomised trial comparing 6 vs. 12-month of capecitabine as adjuvant chemotherapy for patients with stage III colon cancer: final results of the JFMC37-0801 study
por: Tomita, Naohiro, et al.
Publicado: (2019)

Preplanned safety analysis of the JFMC37-0801 trial: a randomized phase III study of six months versus twelve months of capecitabine as adjuvant chemotherapy for stage III colon cancer
por: Suto, Takeshi, et al.
Publicado: (2017)

Mutant KRAS and GNAS DNA Concentrations in Secretin-Stimulated Pancreatic Fluid Collected from the Pancreatic Duct and the Duodenal Lumen
por: Sadakari, Yoshihiko, et al.
Publicado: (2014)

Safety analysis of two different regimens of uracil–tegafur plus leucovorin as adjuvant chemotherapy for high-risk stage II and III colon cancer in a phase III trial comparing 6 with 18 months of treatment: JFMC33-0502 trial
por: Tsuchiya, Takashi, et al.
Publicado: (2014)

Capecitabine and oxaliplatin combined with bevacizumab are feasible for treating selected Japanese patients at least 75 years of age with metastatic colorectal cancer
por: Munemoto, Yoshinori, et al.
Publicado: (2015)

Is the measurement of drain amylase content useful for predicting pancreas-related complications after gastrectomy with systematic lymphadenectomy?
por: Nakanishi, Koki, et al.
Publicado: (2020)

Erratum to: Clinicopathological factors associated with HER2 status in gastric cancer: results from a prospective multicenter observational cohort study in a Japanese population (JFMC44-1101)
por: Matsusaka, Satoshi, et al.
Publicado: (2015)

Clinicopathological factors associated with HER2 status in gastric cancer: results from a prospective multicenter observational cohort study in a Japanese population (JFMC44-1101)
por: Matsusaka, Satoshi, et al.
Publicado: (2015)

Daikenchuto accelerates the recovery from prolonged postoperative ileus after open abdominal surgery: a subgroup analysis of three randomized controlled trials
por: Kono, Toru, et al.
Publicado: (2019)

Initial safety report on the tolerability of modified FOLFOX6 as adjuvant therapy in patients with curatively resected stage II or III colon cancer (JFMC41-1001-C2: JOIN trial)
por: Kotaka, Masahito, et al.
Publicado: (2015)

Treatment using oxaliplatin and S-1 adjuvant chemotherapy for pathological stage III gastric cancer: a multicenter phase II study (TOSA trial) protocol
por: Namikawa, Tsutomu, et al.
Publicado: (2018)

Phase II study of the effectiveness and safety of trastuzumab and paclitaxel for taxane‐ and trastuzumab‐naïve patients with HER2‐positive, previously treated, advanced, or recurrent gastric cancer (JFMC45‐1102)
por: Nishikawa, Kazuhiro, et al.
Publicado: (2016)

Randomized phase II study of daily and alternate-day administration of S-1 for advanced gastric cancer (JFMC43-1003)
por: Tanaka, Hiroaki, et al.
Publicado: (2017)

The clinical impact of Hangeshashinto (TJ-14) in the treatment of chemotherapy-induced oral mucositis in gastric cancer and colorectal cancer: Analyses of pooled data from two phase II randomized clinical trials (HANGESHA-G and HANGESHA-C)
por: Nishikawa, Kazuhiro, et al.
Publicado: (2018)

Surveillance of Esophageal Cancer in the Republic of Uzbekistan from 2000 to 2018
por: Yusupbekov, Abror, et al.
Publicado: (2020)

Randomized phase II study of cetuximab versus irinotecan and cetuximab in patients with chemo-refractory KRAS codon G13D metastatic colorectal cancer (G13D-study)
por: Nakamura, Masato, et al.
Publicado: (2016)

Significance of the mucinous component in the histopathological classification of colon cancer
por: Maeda, Yuji, et al.
Publicado: (2015)

A Methylene Blue–assisted Technique for Harvesting Lymph Nodes After Radical Surgery for Gastric Cancer: A Prospective, Randomized, Controlled Study
por: Aoyama, Toru, et al.
Publicado: (2015)

Double-blind, placebo-controlled, randomized phase II study of TJ-14 (hangeshashinto) for gastric cancer chemotherapy-induced oral mucositis
por: Aoyama, Toru, et al.
Publicado: (2014)

Estradiol Stabilizes p53 Protein in Breast Cancer Cell Line, MCF–7
por: Okumura, Naoki, et al.
Publicado: (2002)

Overexpression of MDM2 in MCF‐7 Promotes Both Growth Advantage and p53 Accumulation in Response to Estradiol
por: Saji, Shigehira, et al.
Publicado: (1999)

An individual patient data meta-analysis of adjuvant therapy with uracil–tegafur (UFT) in patients with curatively resected rectal cancer
por: Sakamoto, J, et al.
Publicado: (2007)

Myocardin-related transcription factor A (MRTF-A) activity-dependent cell adhesion is correlated to focal adhesion kinase (FAK) activity
por: Kishi, Takayuki, et al.
Publicado: (2016)

Wall Shear Stress and T1 Contrast Ratio Are Associated With Embolic Signals During Carotid Exposure in Endarterectomy
por: Oshida, Sotaro, et al.
Publicado: (2018)

Preoperative predictors of postoperative complications after gastric cancer resection
por: Kanda, Mitsuro
Publicado: (2019)

Correction to: Preoperative predictors of postoperative complications after gastric cancer resection
por: Kanda, Mitsuro
Publicado: (2020)

Prospective observational study of the efficacy of oral uracil and tegafur plus leucovorin for stage II colon cancer with risk factors for recurrence using propensity score matching (JFMC46-1201)
por: Sadahiro, Sotaro, et al.
Publicado: (2022)

Multicenter Phase II study of FOLFOX or biweekly XELOX and Erbitux (cetuximab) as first-line therapy in patients with wild-type KRAS/BRAF metastatic colorectal cancer: The FLEET study
por: Soda, Hitoshi, et al.
Publicado: (2015)

Unique solvability of a crack problem with Signorini-type and Tresca friction conditions in a linearized elastodynamic body
por: Kashiwabara, Takahito, et al.
Publicado: (2022)

Gene Selection using a High-Dimensional Regression Model with Microarrays in Cancer Prognostic Studies
por: Kaneko, Shuhei, et al.
Publicado: (2012)

Enhancing the Lasso Approach for Developing a Survival Prediction Model Based on Gene Expression Data
por: Kaneko, Shuhei, et al.
Publicado: (2015)

Phase II clinical study of modified FOLFOX7 (intermittent oxaliplatin administration) plus bevacizumab in patients with unresectable metastatic colorectal cancer—CRAFT study
por: Tezuka, Tohru, et al.
Publicado: (2013)

Phase II study of an oxaliplatin-based regimen for relapsed colon cancer patients treated with oxaliplatin-based adjuvant chemotherapy (INSPIRE study)
por: Ishibashi, Keiichiro, et al.
Publicado: (2021)

Efficacy of CapeOX plus Cetuximab Treatment as a First-Line Therapy for Patients with Extended RAS/BRAF/PIK3CA Wild-Type Advanced or Metastatic Colorectal Cancer
por: Iwamoto, Shigeyoshi, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_926bj4t3t3cc6en5hf3usdhbk3